Subconjunctival Bevacizumab and Recurrent Pterygium
Overview
A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.
Full Title of Study: “Interventional Trial of Subconjunctival Bevacizumab in Recurrent Pterygium”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: July 2012
Detailed Description
1. Pacients with recurrent pterygium 2. Anti-VEGF therapy -Bevacizumab
Interventions
- Drug: Bevacizumab
- One subconjunctival aplication of Bevacizumabe 0,5ml
Arms, Groups and Cohorts
- Experimental: Subconjunctival Bevacizumab
- One aplication of subconjunctival Bevacizumab 0,5 ml
Clinical Trial Outcome Measures
Primary Measures
- Pterygium size after subconjunctival bevacizumab
- Time Frame: 8 weeks
- -Size of recurrent pterygium (measured in mm) after injection
Secondary Measures
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Time Frame: 8 weeks
- -Number of patients with hyposphagma and irritative symptoms after subconjunctival injection
Participating in This Clinical Trial
Inclusion Criteria
- Recurrent pterygium Exclusion Criteria:
- Pregnant or lactating women – History of myocardial infarction – History of stroke
Gender Eligibility: All
Minimum Age: 40 Years
Maximum Age: 80 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Instituto de Olhos de Goiania
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Larissa S Stival, MD, Study Chair, Instituto de Olhos de Goiania
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.